Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat

European Journal of Pharmacology

Volumn 540, Issue 1-3, 2006, Pages 87-90

  Naiker, Dineshree V ^a   Catts, Stanley V ^a,b   Catts, Vibeke S ^a   Bedi, Kuldip S ^c   Bryan Lluka, Lesley J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c BOND UNIVERSITY   (Australia)

Author keywords

Dopamine D2 receptor occupancy; Dosage; In vivo; Olanzapine; Raclopride; Risperidone

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; OLANZAPINE; RACLOPRIDE; RISPERIDONE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM CORTEX; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; STRIATE CORTEX; TISSUE CULTURE;

ALGORITHMS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BINDING, COMPETITIVE; CEREBELLUM; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; RACLOPRIDE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RISPERIDONE; TRITIUM;

EID: 33745005011     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.04.048     Document Type: Article

References (20)

1. Assié M.B., Consul-Denjean W., Koek W., and Newman-Tancredi A. Differential in vivo inhibition of 3H-nemopride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology 75 (2005) 63-68
2. Bischoff S., and Gunst F. Distinct binding patterns of 3H-raclopride and 3H-spiperone at dopamine D2-receptors in vivo in rat brain. Implications for PET studies. J. Recept. Signal Transduct. Res. 17 (1997) 419-431
3. Farde L., Ehrin E., Eriksson L., Greitz T., Hall H., Hedström C.G., Litton J.E., and Sedvall G. Substituted benzamides as ligands for visualisation of dopamine receptor binding in the human brain by positron emission tomography. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 3863-3867
4. Farde L. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231 (1986) 258-262
5. Farde L., Wiesel W.A., Halldin C., and Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45 (1988) 71-76
6. Inoue O., Kobayashi K., Hosoi R., Yamaguchi M., and Gee H. Discrepancies in apparent dopamine D2 receptor occupancy between 3H-raclopride and 3H-N-methylspiperone. J. Neural Transm. 106 (1999) 1099-1104
7. Kapur S., Barlow K., VanderSpek S.C., Javanmard M., and Nobrega J.N. Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychopharmacology (Berl.) 157 (2001) 168-171
8. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
9. Köhler C., Håkan H., Ögren S.O., and Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. Biochem. Pharmacol. 34 (1985) 2251-2259
10. 11C-raclopride studies. J. Cereb. Blood Flow Metab. 16 (1996) 42-52
11. Lammertsma A.A., and Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 4 (1996) 153-158
12. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20 (2000) 423-451
13. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs; in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124 (1996) 57-73
14. Seeman P., Guan H.C., Civelli O., Van Tol H.H.M., Sunahara R.K., and Niznik H.B. The cloned dopamine D2-receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur. J. Pharmacol., Mol. Pharm. 227 (1992) 139-146
15. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38
16. 2 receptor binding of antipsychotics in vivo. Pharmacol. Biochem. Behav. 49 (1994) 165-169
17. Tauscher J., Jones C., Remington G., Zipursky R.B., and Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry 7 (2002) 317-321
18. 2-receptor predicts catalepsy and the suppression of conditioned avoidance response behaviour in rats. Psychopharmacology (Berl.) 150 (2000) 422-429
19. 2-receptor dimers in human and rat brain. FEBS Lett. 441 (1998) 383-386
20. 2A and muscarinic receptors. Psychopharmacology (Berl.) 141 (1999) 267-278